



**Contact:** Marc R. Viscogliosi  
**Tel:** (212) 367-7274, Ext. 2103  
**Email:** [marc.viscogliosi@paradigmospine.com](mailto:marc.viscogliosi@paradigmospine.com)

**FOR IMMEDIATE RELEASE**

**PARADIGM SPINE, LLC ANNOUNCES AVAILABILITY OF MILLIMAN, INC. REPORT ON COST AND POTENTIAL COST OFFSETS ASSOCIATED WITH LUMBAR SPINAL STENOSIS PATIENTS IN A COMMERCIALLY INSURED POPULATION**

**New York, NY October 29, 2015** – Paradigm Spine, LLC, a leading provider of innovative spinal implants, announces the publication of a analysis prepared by Milliman, Inc, titled “Utilization and Cost of Surgery for Lumbar Spinal Stenosis (“LSS”) in a Commercially Insured Population” commissioned by Paradigm Spine, LLC . The report is currently available on the Milliman, Inc. website. Please find a link to the full analysis here: <http://us.milliman.com/insight/2015/Utilization-and-cost-of-surgery-for-lumbar-spinal-stenosis-in-a-commercially-insured-population/>. It is important to note the report should be read in its entirety so as to not be taken out of context. While the findings reflect the research of the authors, Milliman does not intend to endorse any product or organization.

As summarized in the report, “[t]his analysis was intended to quantify the frequency and cost of LSS related decompression and lumbar fusion surgeries in a commercially insured population as well as the portion of cases that had a decompression or lumbar fusion in the preceding 4 years. In addition, [Milliman] modeled the cost impact of replacing a portion of lumbar fusion cases with decompression and use of an [interlaminar] lumbar stabilization (ILS) device.” A 20% - 40% replacement of primary lumbar fusion surgeries with decompression and interlaminar stabilization device could potentially reduce approximately \$0.25 per member per month (PMPM) - \$0.49 PMPM (14% - 28%) of the approximately \$1.77 PMPM allowed for primary lumbar spinal fusion.

As this study continues to add to the wealth of published literature on coflex® interlaminar stabilization worldwide, Marc Viscogliosi, Chairman and CEO of Paradigm Spine, LLC comments, “all interested stakeholders, including patients, physicians, payers, providers and policy-makers, are critically focused on cost-effective healthcare therapeutic solutions which provide sustainable and durable treatment effects to a large patient population. This independent analysis, combined with Paradigm Spine’s long-term clinical data publications, continues to support technologies such as coflex interlaminar stabilization providing improved patient outcomes and cost savings to the healthcare system.”

**About Paradigm Spine, LLC**

Paradigm Spine, LLC was founded in 2004 and remains focused on the design and development of solutions for the disease management of spinal stenosis. The Company's signature product is the coflex® interlaminar stabilization device, which has more than 20 years of clinical history and patients treated in more than 40 countries worldwide.